Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · Tejnaksh Healthcare Limited · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Tejnaksh Healthcare Limited
BSE: 539428
BSE: 539428
Healthcare › Healthcare › Healthcare Services › Healthcare Service Provider
Tejnaksh Healthcare Limited
StateQ4 FY26 filed
Last close · 9 Oct 2026₹12.95
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA22.3 · 0.95 · 7.7
Tejnaksh Healthcare Limited is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 13 | 12 | 12 | 13 | 11 |
| EBITDA (ex other income) | 5 | 4 | 4 | 4 | 3 |
| margin % | 37.5 | 31.4 | 29.7 | 31.6 | 25.7 |
| Owners' profit | 3 | 2 | 0 | 2 | 1 |
| EPS, as reported (₹) | 2.48 | 1.66 | 0.87 | 1.15 | 0.61 |
| ROE % · ROCE % | 13.6 · 15.2 | 8.0 · 10.5 | 7.3 · 10.1 | 8.4 · 12.2 | 4.3 · 5.9 |
| Debt / equity (x) | 0.31 | 0.26 | 0.17 | 0.02 | 0.00 |
| Cash from operations | 9 | 2 | 4 | 0 | 2 |
| Capex | (9) | (1) | (1) | (0) | (1) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Tejnaksh Healthcare Limited · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| Net profit | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.29 | 0.31 | 0.38 | 0.21 | 0.12 | 0.15 | 0.14 | 0.17 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,807 | 45.8 | 12.52 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 14,797 | 78.9 | 15.46 | 41.3 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 10,885 | 22.5 | 7.14 | 26.0 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 7,959 | 29.3 | 13.58 | 29.0 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 6,266 | 64.7 | 5.61 | 24.7 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,732 | 17.8 | 1.77 | 8.8 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,641 | 45.8 | 6.74 | 16.6 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,311 | 21.9 | 3.95 | 15.5 | 18.1 | 22.5 | (8.9) | 52.6 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 21.8 | 22.5 | 10 of 25 | 63% |
| P/B | 0.9 | 2.0 | 6 of 24 | 78% |
| ROCE | 5.6 | 6.1 | 17 of 29 | 43% |
| ROE | 4.3 | 6.0 | 14 of 24 | 44% |
| Debt / Equity | 0.0 | 0.1 | 1 of 23 | 77% |
| EBITDA margin | 33.3 | 25.6 | 7 of 24 | 74% |
| Revenue growth | (20.6) | 20.8 | 23 of 25 | 8% |
| Profit growth | (17.6) | 22.0 | 17 of 25 | 33% |
| Market cap | 26 | 35 | 20 of 30 | 35% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Tejnaksh Healthcare Limited · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 1 Oct 2026 · Reappointment of Independent Director Suhas Thorat approved at 18th AGM | management changes | medium | — | — |
| 1 Oct 2026 · All 4 resolutions passed at 19th AGM with requisite majority | board shareholder meetings | low | — | — |
| 29 Sept 2026 · 19th AGM of Tejnaksh Healthcare held on 29 Sep 2026 via video conferencing | board shareholder meetings | low | — | — |
| 26 Sept 2026 · Trading Window Closed Ahead of Q2 FY27 Financial Results | compliance | minimal | — | — |
| 4 Sept 2026 · Annual Report FY 2025-26 filed; AGM on 29 Sept 2026 | results | high | — | — |
| 4 Sept 2026 · Tejnaksh Healthcare 19th AGM on 29 Sep 2026, director re-appointment and RPTs on agenda | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Q1 FY26-27 results: PAT up on consol basis, standalone revenue dips | results | high | — | — |
| 13 Aug 2026 · Board approves Q1 FY27 results, reappoints independent director | board shareholder meetings | medium | — | — |
| 8 Aug 2026 · Board meeting on Aug 13 to consider Q1 results and reappoint Independent Director | management changes | medium | — | — |
| 19 Jul 2026 · Compliance certificate under SEBI Reg 74(5) for Q1 FY27 | compliance | minimal | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in